Ignite Creation Date:
2024-05-06 @ 9:38 AM
Last Modification Date:
2024-10-26 @ 12:17 PM
Study NCT ID:
NCT03030625
Status:
COMPLETED
Last Update Posted:
2024-07-03
First Post:
2017-01-12
Brief Title:
VMAT for Dominant Intraprostatic Lesion
Sponsor:
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Organization:
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Study Overview
Official Title:
Dose Intensification With a Focal Boost to Dominant Intraprostatic Lesion Using Volumetric Modulated Arc Therapy Image Guided Radiotherapy in Patients With Localized Prostate Cancer
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CaP-VMAT-DIL
Brief Summary:
The aim of this study was to determine the efficacy and safety of the implementation of a program of image-guided focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer PCa of intermediate and high risk criteria NCCN eligible to receive radiotherapy in the Department of Radiation Oncology of HUP Hospital Universitario de La Princesa within the established dose escalation protocol with intensity modulated image-guided radiotherapy IMRT IGRT
Detailed Description:
The aim of this study was to determine the efficacy and safety of the implementation of a program of image-guided focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer PCa of intermediate and high risk criteria NCCN eligible to receive radiotherapy in the Department of Radiation Oncology of HUP Hospital Universitario de La Princesa within the established dose escalation protocol with intensity modulated image-guided radiotherapy IMRT IGRT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None